An exploratory, open label, multicenter parallel group study to evaluate the effects of single and repeat dosing of SB-751689 [ronacaleret] (400 mg or 100 mg) or rhPTH (1-34) [teriparatide] on the fractional renal excretion of calcium and phosphate in healthy postmenopausal females.

Trial Profile

An exploratory, open label, multicenter parallel group study to evaluate the effects of single and repeat dosing of SB-751689 [ronacaleret] (400 mg or 100 mg) or rhPTH (1-34) [teriparatide] on the fractional renal excretion of calcium and phosphate in healthy postmenopausal females.

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Sep 2009

At a glance

  • Drugs Ronacaleret; Teriparatide
  • Indications Postmenopausal osteoporosis
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 11 Sep 2009 Results presented at the 31st Annual Meeting of the American Society for Bone and Mineral Research.
    • 18 Jun 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top